84-3349-79　［取扱停止］VEGFR2, Phosphorylated (Tyr1054) (Vascular Endothelial Growth Factor Receptor 2, VEGF Receptor 2, VEGFR 2, VEGFR-2, VEGFR, CD309 Antigen, Fetal Liver Kinase 1, FLK1, Kinase Insert Domain Receptor, KDR, KRD1, Ly73, Protein Tyrosine Kinase Receptor FLK1) (AP) 100ul　217870-AP

特徴

• The Flt gene family of receptor tyrosine kinases includes Flt-1, KDR/Flk-1, Flt-3, and Flt-4.
• They encode receptors for VEGF, characterized by seven Ig-loops within their extracellular domain and a split kinase domain within the cytoplasmic domain.
• VEGF is an important angiogenic factor of many solid tumors and is also involved in the differentiation of endothelial cells.
• Flt-1 (Fms-like tyrosine kinase, VEGF-R1) is expressed on endothelial cells and on the common precursors of endothelial and hematopoietic stem cells.
• KDR (Flk-1, VEGF-R2) is the principal receptor involved in VEGF signaling.
• KDR is expressed on endothelial cells and stimulates angiogenesis, but is also expressed on bone marrow cells, and is thought to play a role in driving the proliferation of most or all leukemic cells.
• Flt3 (also known as Flk-2) is a class III receptor tyrosine kinase that is closely related to c-Kit and c-Fms.
• It is expressed in primitive hematopoietic cells and its ligand exerts proliferative effects on these cells in co-operation with other cytokines.
• Applications:Suitable for use in Western Blot.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Control:CSF-1 treated PAE cell lysate, transfected with CSF/KDR.
• Storage and Stability:Store product at 4°C.
• DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• For maximum recovery of product, centrifuge the original vial prior to removing the cap.
• Note: Applications are based on unconjugated antibody.